STOCK TITAN

KalVista Pharmaceuticals (KALV) Total Assets by Year

KALV

KalVista Pharmaceuticals, Inc. closed fiscal year 2025 with $250.8M in total assets, $155.4M in total liabilities and $116.8M in shareholder equity. Total assets rose 6.5% from the prior fiscal year. The table below carries 12 fiscal years, from 2013 to 2025, and the quarters KalVista Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Total Assets $250.8M
Total Liabilities $155.4M
Total Equity $116.8M
YoY +6.5%
5Y CAGR +22.1%
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

KALV Balance Sheet by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KTFY2410-KTFY2310-KFY2210-KFY2110-KFY2010-QFY19FilingFY1810-KFY1710-KFY1610-QFY1410-KFY1310-K
Total Assets$250.8M+6.5%$235.4M+28.5%$183.2M-10.1%$203.9M-25.0%$272.0M+194.0%$92.5M-21.7%$118.1M+92.4%$61.4M+78.7%$34.3M-30.9%$49.7M$6.6MN/A
Total Liabilities$155.4M+439.1%$28.8M+30.0%$22.2M+18.0%$18.8M+26.8%$14.8M+68.9%$8.8M-59.0%$21.4M-37.3%$34.1M+1031.1%$3.0M-54.3%$6.6M$50.8MN/A
Total Equity$116.8M-46.3%$217.6M+35.1%$161.0M-13.0%$185.1M-28.0%$257.2M+207.1%$83.8M-13.4%$96.7M+255.0%$27.3M-13.0%$31.3M-27.3%$43.1M-$44.2Mn/m-$33.7M

KALV Balance Sheet by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-KTQ3'2510-QQ2'25FilingQ1'25FilingQ4'2410-KTQ3'2410-QQ2'24FilingQ1'24Filing
Total Assets$328.9M+64.3%$335.4M+42.5%$339.9M+111.4%$215.5M+7.6%$250.8M+6.5%$294.8M+158.7%$160.8M+15.9%$200.2M+24.9%$235.4M+28.5%$114.0M-44.0%$138.7M-14.8%$160.3M-12.1%
Total Liabilities$348.6M+1708.8%$338.1M+1073.0%$322.9M+2525.2%$156.1M+709.8%$155.4M+439.1%$130.5M+710.4%$12.3M-49.4%$19.3M-8.2%$28.8M+30.0%$16.1M-15.4%$24.3M+27.7%$21.0M+18.3%
Total Equity-$19.7M-110.9%-$2.7M-101.2%$17.0M-88.6%$59.4M-67.1%$116.8M-46.3%$164.4M+67.9%$148.5M+29.8%$180.9M+29.9%$217.6M+35.1%$97.9M-46.9%$114.4M-20.4%$139.3M-15.3%

What total assets means

Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.

More KalVista Pharmaceuticals, Inc. financials

Frequently Asked Questions

KalVista Pharmaceuticals, Inc. closed fiscal year 2025 with $250.8M in total assets, $155.4M in total liabilities and $116.8M in shareholder equity.

KalVista Pharmaceuticals, Inc. (KALV) total assets rose by 6.5% year over year, from $235.4M to $250.8M in fiscal year 2025.

KalVista Pharmaceuticals, Inc. (KALV) reported $328.9M in total assets in Q1 2026. This represents an increase of 64.3% from the same quarter a year earlier.

Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what KalVista Pharmaceuticals, Inc. (KALV) reported on that line in every period on record.